Monopar: Radiopharmaceutical Company With 2 Radioisotope Development Pathways

Company Overview - Monopar Therapeutics Inc. (NASDAQ: MNPR) has initiated dosing of its first patient with the radiotherapeutic candidate MNPR-101-Lu aimed at treating advanced solid tumors [4] Unique Selling Proposition - The radiotherapeutic candidate MNPR-101-Lu is highlighted as a unique offering in the market, although specific differentiating factors are not detailed in the provided content [4]